The CIK cells stimulated with combination of IL-2 and IL-15 provide an improved cytotoxic capacity against human lung adenocarcinoma

Tumor Biology

Volumn 35, Issue 3, 2014, Pages 1997-2007

  Wei, Chuanyu ^a   Wang, Wenju ^a   Pang, Wei ^a   Meng, Mingyao ^a   Jiang, Lihong ^a   Xue, Sha ^a   Xie, Yanhua ^a   Li, Ruhong ^a   Hou, Zongliu ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Cytokine induced killer; IL 15; IL 2; Lung adenocarcinoma; Tumor cytotoxicity

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TUMOR REGRESSION;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; CELL CULTURE TECHNIQUES; CYTOKINE-INDUCED KILLER CELLS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-15; INTERLEUKIN-2; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84898884888     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1265-2     Document Type: Article

References (36)

1. Du L, Wang H, Xiong T, et al. The polymorphisms in the MGMT gene and the risk of cancer: a meta-analysis. Tumour Biol. 2013;34:3227-37.
2. Li Y, Huang Y, Cao YS, et al. Assessment of the association between XRCC1 Arg399Gln polymorphism and lung cancer in Chinese. Tumour Biol. 2013. doi: 10.1007/s13277-013-0950-5.
3. Sankpal UT, Pius H, Khan M, et al. Environmental factors in causing human cancers: emphasis on tumorigenesis. Tumour Biol. 2012;33:1265-74.
4. Moran C. Importance of molecular features of non-small cell lung cancer for choice of treatment. Am J Pathol. 2011;178:1940-8.
5. Stroncek D, Berlyne D, Fox B, et al. Developments in clinical cell therapy. Cytotherapy. 2010;12:425-8.
6. Li XD, Xu B, Wu J, et al. Review of Chinese clinical trials on CIK cell treatment for malignancies. Clin Transl Oncol. 2012;14:102-8.
7. Linn YC, Hui KM. Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol. 2010;2010:435745.
8. Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer. 2011;2:363-8.
9. Jiang J, Wu C, Lu B. Cytokine-induced killer cells promote antitumor immunity. J Transl Med. 2013;11:83.
10. Sangodkar J, Katz S, Melville H, Narla G. Lung adenocarcinoma: lessons in translation from bench to bedside. Mt Sinai J Med. 2010;77:597-605.
11. Schmidt-Wolf IG, Lefterova P, Mehta BA, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol. 1993;21:1673-9.
12. Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 1994;153:1687-96.
13. Sangiolo D, Martinuzzi E, Todorovic M, et al. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int Immunol. 2008;20:841-8.
14. Verneris MR, Karami M, Baker J, Jayaswal A, Negrin RS. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood. 2004;103:3065-72.
15. Kuci S, Rettinger E, Voss B, et al. Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation. Haematologica. 2010;95:1579-86.
16. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001;97:14-32.
17. Waldmann TA, Dubois S, Tagaya Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity. 2001;14:105-10.
18. Judge AD, Zhang X, Fujii H, Surh CD, Sprent J. Interleukin 15 controls both proliferation and survival of a subset of memory-phenotype CD8(+) T cells. J Exp Med. 2002;196:935-46.
19. Zhang J, Sun R, Wei H, Tian Z. Characterization of interleukin-15 gene-modified human natural killer cells: implications for adoptive cellular immunotherapy. Haematologica. 2004;89:338-47.
20. Kobayashi H, Dubois S, Sato N, et al. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood. 2005;105:721-7.
21. Kim HM, Lim J, Park SK, et al. Antitumor activity of cytokine-induced killer cells against human lung cancer. Int Immunopharmacol. 2007;7:1802-7.
22. Liu P, Chen L, Huang X. The antitumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo. Cancer Biother Radiopharm. 2009;24:91-8.
23. Zhong R, Teng J, Han B, Zhong H. Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother. 2011;60:1497-502.
24. Yang L, Ren B, Li H, et al. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother. 2013;62:65-73.
25. Wang Y, Dai H, Li H, et al. Growth of human colorectal cancer SW1116 cells is inhibited by cytokine-induced killer cells. Clin Dev Immunol. 2011;2011:621414.
26. Zhang L, Hou Y, Zhang J, Hu J, Zhang K. Cytotoxicity of cytokine-induced killer cells targeted by a bispecific antibody to gastric cancer cells. Oncol Lett. 2013;5:1826-32.
27. Su X, Zhang L, Jin L, et al. Immunotherapy with cytokine-induced killer cells in metastatic renal cell carcinoma. Cancer Biother Radiopharm. 2010;25:465-70.
28. Gammaitoni L, Giraudo L, Leuci V, et al. Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features. Clin Cancer Res. 2013;19:4347.
29. Rettinger E, Meyer V, Kreyenberg H, et al. Cytotoxic capacity of IL-15-stimulated cytokine-induced killer cells against human acute myeloid leukemia and rhabdomyosarcoma in humanized preclinical mouse models. Front Oncol. 2012;2:32.
30. Rettinger E, Kuci S, Naumann I, et al. The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy. 2012;14:91-103.
31. Thulesen S, Nissen MH, Odum N, Ropke C. Induction of cytotoxic CD8+CD56+ T cells from human thymocytes by interleukin-15. J Interferon Cytokine Res. 2001;21:905-11.
32. Szopinski J, von Kleist S, Rowinska-Zakrzewska E, Panorska A, Roginska E, Rogala E. Interferon gamma and interleukin-2 secretion in whole blood cell cultures from small-cell lung cancer patients. Tumour Biol. 2001;22:72-6.
33. Fehniger TA, Shah MH, Turner MJ, et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol. 1999;162:4511-20.
34. Ross ME, Caligiuri MA. Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response. Blood. 1997;89:910-8.
35. Carson WE, Giri JG, Lindemann MJ, et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med. 1994;180:1395-403.
36. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol. 1999;19:2690-8.